enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · IEX Real-Time Price · USD
15.00
-0.26 (-1.70%)
Apr 24, 2024, 10:47 AM EDT - Market open
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
The company was founded in 2023 and is based in Saint-Laurent, Canada.
enGene Holdings Inc.
| Country | Canada |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Jason D. Hanson Esq., J.D. |
Contact Details
Address: 4868 Rue Levy, Suite 220 Saint-laurent, A8 H4R 2P1 Quebec, Canada | |
| Phone | (514) 332-4888 |
| Website | engene.com |
Stock Details
| Ticker Symbol | ENGN |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001980845 |
| ISIN Number | CA29286M1059 |
| SIC Code | 2836 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | ARS | Filing |
| Apr 18, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2024 | 424B3 | Prospectus |
| Mar 11, 2024 | 10-Q | Quarterly Report |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 5, 2024 | EFFECT | Notice of Effectiveness |
| Mar 5, 2024 | 424B3 | Prospectus |
| Feb 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |